Good Results for Zone MPC-Based Artificial Pancreas

Share this content:
Good Results for Zone MPC-Based Artificial Pancreas
Good Results for Zone MPC-Based Artificial Pancreas

THURSDAY, June 15, 2017 (HealthDay News) -- A zone model predictive control (MPC)-based artificial pancreas (AP) system improves glycemic control in a home-use environment, according to a study published online June 5 in Diabetes Care.

Gregory P. Forlenza, M.D., from the University of Colorado Denver, and colleagues conducted an outpatient randomized crossover trial to examine the safety and efficacy of a zone-MPC-based AP system versus sensor-augmented pump (SAP) therapy. Nineteen adults participated in the crossover study involving two weeks of use of a smartphone-based AP system and two weeks of SAP therapy.

The researchers found that AP correlated with improved percent time at 70 to 140 mg/dL (48.1 versus 39.2 percent) and time at 70 to 180 mg/dL (71.6 versus 65.2 percent) compared with SAP and with decreased percent time <70 mg/dL (1.3 versus 2.7 percent); AP also correlated with decreased median glucose (141 versus 153 mg/dL) and glycemic variability (standard deviation, 52 versus 55 mg/dL) versus SAP. Improvement in overnight control was seen with AP, as measured by mean glucose at 6 a.m. (140 versus 158 mg/dL). The AP and SAP arms had similar insulin infusion set failures and sensor failures. Better glycemic outcomes were seen with a higher percent time in closed loop.

"This project represents the first home-use AP study attempting to provoke and detect component failure while successfully maintaining safety and effective glucose control," the authors write.

Several authors disclosed financial ties to the pharmaceutical and medical device industries, and three authors own patents related to the underlying MPC algorithms used in the study.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »